{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High+Risk+Solid+Tumors&page=7",
    "query": {
      "condition": "High Risk Solid Tumors",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 220,
    "total_pages": 22,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High+Risk+Solid+Tumors&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High+Risk+Solid+Tumors&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T16:42:14.067Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00003173",
      "title": "High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors",
        "Childhood Germ Cell Tumor",
        "Extragonadal Germ Cell Tumor",
        "Ovarian Cancer",
        "Retinoblastoma",
        "Testicular Germ Cell Tumor",
        "Unspecified Adult Solid Tumor, Protocol Specific",
        "Unspecified Childhood Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "thiotepa",
          "type": "DRUG"
        },
        {
          "name": "autologous bone marrow transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 36,
      "start_date": "1997-09",
      "completion_date": "2003-05",
      "has_results": false,
      "last_update_posted_date": "2013-03-07",
      "last_synced_at": "2026-10-09T16:42:14.067Z",
      "location_count": 2,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003173"
    },
    {
      "nct_id": "NCT03836352",
      "title": "Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Hepatocellular Carcinoma",
        "Non-small Cell Lung Cancer",
        "Bladder Cancer",
        "Microsatellite Instability-High"
      ],
      "interventions": [
        {
          "name": "DPX-Survivac",
          "type": "OTHER"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "ImmunoVaccine Technologies, Inc. (IMV Inc.)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 184,
      "start_date": "2018-12-21",
      "completion_date": "2023-12-31",
      "has_results": false,
      "last_update_posted_date": "2022-03-31",
      "last_synced_at": "2026-10-09T16:42:14.067Z",
      "location_count": 15,
      "location_summary": "Tucson, Arizona • Los Angeles, California • Boca Raton, Florida + 12 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Port Saint Lucie",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03836352"
    },
    {
      "nct_id": "NCT02859857",
      "title": "Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "BXQ-350",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 86,
      "start_date": "2016-09-01",
      "completion_date": "2020-06-15",
      "has_results": false,
      "last_update_posted_date": "2021-07-22",
      "last_synced_at": "2026-10-09T16:42:14.067Z",
      "location_count": 4,
      "location_summary": "Lexington, Kentucky • Albuquerque, New Mexico • Cincinnati, Ohio + 1 more",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02859857"
    },
    {
      "nct_id": "NCT05135975",
      "title": "A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neuroblastoma",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nationwide Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Months",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Months to 40 Years"
      },
      "enrollment_count": 86,
      "start_date": "2022-07-20",
      "completion_date": "2029-12",
      "has_results": false,
      "last_update_posted_date": "2025-08-12",
      "last_synced_at": "2026-10-09T16:42:14.067Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Aurora, Colorado • Washington D.C., District of Columbia + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05135975"
    },
    {
      "nct_id": "NCT03436563",
      "title": "M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Colon Adenocarcinoma",
        "High-Frequency Microsatellite Instability",
        "Metastatic Malignant Solid Neoplasm",
        "Rectal Adenocarcinoma",
        "Refractory Colorectal Carcinoma",
        "Stage IV Colon Cancer AJCC v8",
        "Stage IV Rectal Cancer AJCC v8",
        "Stage IVA Colon Cancer AJCC v8",
        "Stage IVA Rectal Cancer AJCC v8",
        "Stage IVB Colon Cancer AJCC v8",
        "Stage IVB Rectal Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Anti-PD-L1/TGFbetaRII Fusion Protein M7824",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2018-03-07",
      "completion_date": "2023-08-08",
      "has_results": true,
      "last_update_posted_date": "2024-11-27",
      "last_synced_at": "2026-10-09T16:42:14.067Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03436563"
    },
    {
      "nct_id": "NCT03568539",
      "title": "IBI308 in Subjects With Advanced/Metastatic Solid Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced/Metastatic Solid Malignancies"
      ],
      "interventions": [
        {
          "name": "IBI308",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Innovent Biologics (Suzhou) Co. Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2018-06-27",
      "completion_date": "2020-12-07",
      "has_results": true,
      "last_update_posted_date": "2021-06-01",
      "last_synced_at": "2026-10-09T16:42:14.067Z",
      "location_count": 7,
      "location_summary": "Orange, California • Atlanta, Georgia • Detroit, Michigan + 4 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03568539"
    },
    {
      "nct_id": "NCT04293094",
      "title": "Study of AMG 650 in Adult Participants With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "AMG 650",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Volastra Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 66,
      "start_date": "2020-03-11",
      "completion_date": "2023-02-15",
      "has_results": false,
      "last_update_posted_date": "2023-08-24",
      "last_synced_at": "2026-10-09T16:42:14.067Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Santa Monica, California • Indianapolis, Indiana + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04293094"
    },
    {
      "nct_id": "NCT02987166",
      "title": "HDCRT Plus Pembrolizumab in Advanced Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "High-Dose Conformal Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "James Larner, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2017-03-21",
      "completion_date": "2020-02-10",
      "has_results": true,
      "last_update_posted_date": "2026-06-15",
      "last_synced_at": "2026-10-09T16:42:14.067Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02987166"
    },
    {
      "nct_id": "NCT05563272",
      "title": "89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cervical Cancer",
        "Colorectal Cancer",
        "Esophageal Cancer",
        "Gastric Cancer",
        "Glioblastoma Multiforme",
        "Cholangiocarcinoma",
        "Hepatocellular Carcinoma",
        "Head and Neck Squamous Cell Carcinoma",
        "Nasopharyngeal Carcinoma",
        "Non Small Cell Lung Cancer",
        "Small Cell Lung Cancer",
        "Epithelial Ovarian Cancer",
        "Pancreatic Ductal Adenocarcinoma",
        "Soft Tissue Sarcoma",
        "Gastric Adenocarcinoma",
        "Malignant Mesothelioma (MM)",
        "Von Hippel Lindau",
        "Bladder Cancer",
        "Bladder Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "89Zr-girentuximab for PET/CT imaging of CAIX positive tumors",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Telix Pharmaceuticals (Innovations) Pty Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "18 Years to 95 Years"
      },
      "enrollment_count": 11,
      "start_date": "2023-06-06",
      "completion_date": "2025-05-09",
      "has_results": false,
      "last_update_posted_date": "2025-07-10",
      "last_synced_at": "2026-10-09T16:42:14.067Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Miami, Florida • Boston, Massachusetts + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Traverse City",
          "state": "Michigan"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05563272"
    },
    {
      "nct_id": "NCT04180371",
      "title": "Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor Historically Known for High EphA2 Expression",
        "Urothelial Cancer",
        "Ovarian Cancer",
        "Non-small Cell Lung Cancer",
        "Head and Neck Cancer",
        "Triple Negative Breast Cancer",
        "Gastric/Upper Gastrointestinal Cancer"
      ],
      "interventions": [
        {
          "name": "BT5528",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BicycleTx Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 288,
      "start_date": "2019-11-07",
      "completion_date": "2027-07-31",
      "has_results": false,
      "last_update_posted_date": "2025-11-17",
      "last_synced_at": "2026-10-09T16:42:14.067Z",
      "location_count": 12,
      "location_summary": "Encinitas, California • Orange, California • Denver, Colorado + 9 more",
      "locations": [
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04180371"
    }
  ]
}